The healing peptides are among the most used and least studied compounds on this site. Nearly every dose here is community convention, so the useful questions are practical: how people usually run them, for how long, and what to watch for.
BPC-157 and TB-500 have almost no human trial data. The doses people use come from user reports and clinic guides.
ARA-290 is the exception: Phase 2 trials used 4 mg under the skin daily for 28 days for small-fiber nerve damage.
Since April 2026, BPC-157, TB-500 and KPV are no longer on FDA’s Category 2 list of compounding substances with safety concerns, because their nominations were withdrawn. In July 2026 FDA’s advisory committee voted 8–6 to recommend allowing them in compounding, against FDA staff advice. The vote is advice; FDA makes the final decision.
| Compound | Evidence | Common dose | Frequency | Cycle, first 26 weeks |
|---|---|---|---|---|
| BPC-157Tissue-repair peptide | Preclinical | 250–500 mcg, 1–2× daily | 1–2× daily | 6 weeks on, 3 off |
| TB-500Tissue-repair peptide | Preclinical | 2–2.5 mg twice weekly, then weekly | 2× per week, then weekly | Load 5 weeks, maintain 6, then 6 off |
| BPC-157 + TB-500Repair blend | Blend | 250–500 mcg of each, daily | Once daily | 6 weeks on, 3 off |
| GHK-CuCopper peptide | Human studies | 1–2 mg daily | Once daily | 6 weeks on, 3 off |
| GLOW blendSkin and repair blend | Blend | 1–2 mg GHK-Cu share, daily | Once daily | 6 weeks on, 3 off |
| KLOW blendSkin, repair and anti-inflammatory blend | Blend | 1–2 mg GHK-Cu share, daily | Once daily | 6 weeks on, 3 off |
| KPVAnti-inflammatory peptide | Preclinical | 200–500 mcg daily | Once daily | 8 weeks on, 8 off |
| CartalaxShort bioregulator peptide | Preclinical | ~200 mcg daily for 10–20 days | Once daily during a course | 2-week course, about every 4 months |
| ARA-290Tissue-protective peptide (EPO-derived) | Human studies | 4 mg daily for 28 days | Once daily | One 4-week course |
Each draw is worked out for the vial and water shown. The calculator can plan a whole run, including how many vials it takes.
| Period | Dose | Draw |
|---|---|---|
| Weeks 1–684 doses | 250 mcg | 10 units |
Mixed as 5 mg + 2 mL (2.5 mg/mL). One vial holds 20 doses, about 10 days at this pace.
Twice a day, under the skin and as close to the injury as practical.
| Period | Dose | Draw |
|---|---|---|
| Weeks 1–52× per week, 10 doses | 2.5 mg | 50 units |
| Weeks 6–111× per week, 6 doses | 2 mg | 40 units |
Mixed as 10 mg + 2 mL (5 mg/mL). One vial holds 4 doses at 2.5 mg, or 5 at 2 mg.
Twice a week while loading, then once a week. It’s said to act body-wide, so the site matters less.
| Period | Dose | Draw |
|---|---|---|
| Weeks 1–642 doses | 250 mcg | 10 units |
Mixed as 5 + 5 mg + 2 mL (2.5 mg/mL BPC-157). One vial holds 20 doses, about 2.9 weeks at this pace.
Dosed by the BPC-157 share. Each 250 mcg draw also carries 250 mcg of TB-500.
| Period | Dose | Draw |
|---|---|---|
| Days 1–2828 doses | 4 mg | 40 units |
Mixed as 10 mg + 1 mL (10 mg/mL). One vial holds 2 doses, about 3 days at this pace.
The dose used in the sarcoidosis and type 2 diabetes nerve-pain trials.
Running one peptide at a time is the only way to tell what helped, and which one caused a reaction.
Note pain (0 to 10), range of motion and any site reactions each week. With community protocols, your own log is the only evidence you’ll have.
BPC-157 is usually injected near the injury. TB-500 is said to act body-wide, so it can go anywhere.
CommunityNo peptide replaces rest, physical therapy or gradually loading the injured tissue.
In a premixed blend you can’t change one peptide without the other. Separate vials are easier to adjust.
At 250 mcg twice a day, a 5 mg vial lasts 10 days. The calculator’s supply planner shows how many vials a full run needs.
Doses tagged Community come from public dosing guides and user reports, checked against at least two of them. Those sites aren’t named here because many of them sell peptides or earn commissions on them.
Each compound’s page lists its own sources.
The approved GLP-1 drugs, the newer investigational ones, and fat-loss peptides with far less evidence.
GHRH analogs, ghrelin-receptor agonists, tesamorelin and IGF-1 LR3.
Copper peptides, a cosmetic peptide and the two melanotans.
Selank, Semax, their blend, Adamax, Pinealon, DSIP and Cerebrolysin.
NAD+, MOTS-c, SS-31, glutathione and the bioregulator courses.
PT-141, hCG, kisspeptin-10 and oxytocin.
Thymosin alpha-1, Thymalin, KPV and VIP.